Literature DB >> 9792075

Animal models of pneumocystosis.

E Dei-Cas1, M Brun-Pascaud, V Bille-Hansen, A Allaert, E M Aliouat.   

Abstract

As in vitro culture systems allowing to isolate Pneumocystis samples from patients or other mammal hosts are still not available, animal models have critical importance in Pneumocystis research. The parasite was reported in numerous mammals but P. carinii pneumonia (PCP) experimental models were essentially developed by using rats, mice, rabbits and ferrets. The rat treated with corticosteroids for 9-12 weeks is a useful PCP model. Like laboratory rats, conventional mice develop PCP after prolonged corticosteroid administration. The ferret (Mustela putorius furo) also develop PCP under corticosteroid regime. Whilst bronchoalveolar lavage (BAL) is really difficult to perform on live laboratory rodents, serial BAL sampling can be performed on live ferrets. Rabbits currently develop spontaneous PCP at weaning without corticosteroid administration. For this reason this model has been used for studying the host immune response as well as Pneumocystis-surfactant interactions. Pigs and horses also develop spontaneous PCP. Treated with corticosteroids, piglets develop extensive PCP and could be used as a non-rodent model. Pneumocystis was detected in many non-human primates. Primates could represent a source of parasites taxonomically related to P. carinii sp. f. hominis. Moreover, primates might be used as experimental hosts to human Pneumocystis. A marked variability of parasite levels among corticosteroid-treated animals and the fact that the origin of the parasite strain remains unknown, are important drawbacks of the corticosteroid-treated models. For these reasons, inoculated animal models of PCP were developed. The intratracheal inoculation of lung homogenates containing viable parasites in corticosteroid-treated non-latently infected rats resulted in extensive, reproducible Pneumocystis infections. Extensive PCP can be obtained within 5-7 weeks, whilst 9-12 weeks are needed in the classical model. The severe combined immunodeficiency (SCID) mouse inoculated by nasal route and the athymic nude rats intratracheally inoculated were used to test the infectivity of Pneumocystis samples coming from cultures or from different hosts. They were also used to test the anti-Pneumocystis activity of antimicrobial molecules.

Entities:  

Mesh:

Year:  1998        PMID: 9792075     DOI: 10.1111/j.1574-695X.1998.tb01201.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  20 in total

Review 1.  Genetics of surface antigen expression in Pneumocystis carinii.

Authors:  J R Stringer; S P Keely
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

2.  Role of ADP-ribosyltransferase activity of pertussis toxin in toxin-adhesin redundancy with filamentous hemagglutinin during Bordetella pertussis infection.

Authors:  S Alonso; K Pethe; N Mielcarek; D Raze; C Locht
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

3.  Pneumocystis carinii f. sp. hominis is not infectious for SCID mice.

Authors:  Isabelle Durand-Joly; El Moukhtar Aliouat; Céline Recourt; Karine Guyot; Nadine François; Michèle Wauquier; Daniel Camus; Eduardo Dei-Cas
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

4.  Therapeutic efficacies of GW471552 and GW471558, two new azasordarin derivatives, against pneumocystosis in two immunosuppressed-rat models.

Authors:  Elena Jimenez; Antonio Martínez; El Moukhtar Aliouat; Jesus Caballero; Eduardo Dei-Cas; Domingo Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

5.  Development of a rapid real-time PCR assay for quantitation of Pneumocystis carinii f. sp. carinii.

Authors:  Hans Henrik Larsen; Joseph A Kovacs; Frida Stock; Vibeke H Vestereng; Bettina Lundgren; Steven H Fischer; Vee J Gill
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

6.  New rat model of Pneumocystis pneumonia induced by anti-CD4(+) T-lymphocyte antibodies.

Authors:  Timothy D Thullen; Alan D Ashbaugh; Kieran R Daly; Michael J Linke; Paul E Steele; Peter D Walzer
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

7.  Genetic variation at the mitochondrial large-subunit rRNA locus of Pneumocystis isolates from simian immunodeficiency virus-infected rhesus macaques.

Authors:  Karen A Norris; Hans Wildschutte; Jennifer Franko; Kathryn F Board
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

8.  Immunocompetent hosts as a reservoir of pneumocystis organisms: histological and rt-PCR data demonstrate active replication.

Authors:  M Chabé; E Dei-Cas; C Creusy; L Fleurisse; N Respaldiza; D Camus; I Durand-Joly
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-01-08       Impact factor: 3.267

9.  Eighty-kilodalton N-terminal moiety of Bordetella pertussis filamentous hemagglutinin: adherence, immunogenicity, and protective role.

Authors:  Sylvie Alonso; Nathalie Reveneau; Kévin Pethe; Camille Locht
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

10.  In vitro and in vivo activity of iclaprim, a diaminopyrimidine compound and potential therapeutic alternative against Pneumocystis pneumonia.

Authors:  E M Aliouat; E Dei-Cas; N Gantois; M Pottier; C Pinçon; S Hawser; A Lier; D B Huang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-01-12       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.